Cardio Diagnostics Expands IP Portfolio With China Patent

Cardio Diagnostics Holdings Inc. is bolstering its IP portfolio with a patent from Chinese regulatory authorities.

The Middle Kingdom’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (UIRF) for a Chinese patent application titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease.”

“We are excited to receive the Notice of Allowance in China as it represents a significant step toward our goal to continue to expand and strengthen our IP position,” Cardio Diagnostics Founder/CEO Meesha Dogan, Ph.D., said. “As a precision medicine company building solutions that are backed by a robust and growing IP portfolio, we are committed to improving healthcare outcomes globally.”
 
The patent is exclusively licensed to Cardio Diagnostics from UIRF and was co-invented by Dogan, Ph.D., (CEO), and Robert Philibert, M.D., Ph.D., founder/chief medical officer. A Notice of Allowance means the Chinese Patent Office has determined the invention meets all patentability requirements. After paying the required fees, the Chinese patent will be issued. Patents have already been granted to the same family of intellectual property claims in the United States and Europe. 
 
“At the UIRF, we are dedicated to supporting innovation that has the potential to transform healthcare and save lives globally,” UIRF Executive Director Marie Kerbeshian Ph.D., said. “Cardio Diagnostics is a shining example of the work happening here at the University of Iowa and its global impact. We are thrilled to be a part of their journey. We believe their solutions driven by artificial intelligence for the prevention and early detection of heart disease will have a profound impact on patient outcomes, and we look forward to seeing their continued success in America and beyond.”
 
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company develops and commercializes clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. Cardio Diagnostics aims to improve the prevention, early detection, and treatment of cardiovascular disease. 
 
The University of Iowa Research Foundation is part of the University of Iowa Office of the Vice President for Research, which provides researchers and scholars with resources, guidance, and inspiration to secure funding, collaborate, innovate, and forge frontiers of discovery.